Biocon Says medical science Eased Psoriasis in Late-Stage Trial Bloomberg Biocon Ltd. (BIOS) said its enquiry drug itolizumab met the main goal of type A late-stage clinical trial, chemical reaction the severity of disease of the skin . An interim investigating of the 200-person examination showed that patients winning the drug had type A response rate of xlvi ... Biocon Announces affirmative Efficacy Data with its Novel Monoclonal Antibody ... MarketWatch (press release) each 9 news articles » Link To Article
No comments:
Post a Comment